Keros Therapeutics, Inc. - 10-Q Filing
Keros Therapeutics reports Q3 2026 financial results with ongoing R&D and G&A expenditures across Rivatercept, Elritercept, and Cibotercept programs.
Tickers: $KROS
More Regulatory news
- GROOVE BOTANICALS INC. - 10-Q Filing
- Johnson Controls International plc - 10-K Filing
- OLD NATIONAL BANCORP /IN/ - 8-K Filing
- AMTECH SYSTEMS INC - 8-K Filing
- REGIONAL HEALTH PROPERTIES, INC - 8-K Filing
- Bitwise Avalanche ETF - 8-K Filing
- MiNK Therapeutics, Inc. - 10-Q Filing
- Future Vision II Acquisition Corp. - 10-Q Filing
- THUNDER MOUNTAIN GOLD INC - 10-Q Filing
- MiNK Therapeutics, Inc. - 8-K Filing